Feb 19 – U.S. health authorities are looking to approve a fourth dose of COVID-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter.
The Food and Drug Administration was reviewing data on the approval of the second dosage for the RNA messenger agent from Pfizer Inc (PFE.N) and our partner BioNTech SE (22UAy.DE) and the Moderna Inc (MRNA.O) terms, report. added.
The FDA did not immediately respond to the request for comment.
The agency last month set a deadline to receive the recommended dose of COVID-19 vaccine from Pfizer and BioNTech and Moderna, in an effort to provide better protection soon after the Omicron variant.
Planning is still in its early stages, and approval will depend on deciding whether a second booster should be approved for all adults or certain age groups, and whether it should direct Omicron variants or be done differently, the report said.
He added that there was no final decision and that it would be necessary to make encouraging shots available early if something different appeared.
The United States reported that 2,323 people died on Friday, bringing the total to 936,523.